John Willis, DO
Internal Medicine · Mansfield, TXNPI 1205891207
Payments from drug & device makers
Across 135 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$425
- Novo Nordisk$312
- Lilly USA, LLC$285
- Pfizer$201
- Abbott$147
- AbbVie$114
- plus $829 from 23 others
What the payments were for
- Food & beverage$2,313100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $425 |
| Novo Nordisk | 21 | $312 |
| Lilly USA, LLC | 19 | $285 |
| Pfizer | 10 | $201 |
| Abbott | 6 | $147 |
| AbbVie(2 entities) | 6 | $114 |
| Amgen | 5 | $101 |
| GSK | 5 | $88 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $60 |
| Alkermes, Inc. | 2 | $46 |
| Boehringer Ingelheim | 2 | $42 |
| Sanofi Pasteur Inc. | 3 | $41 |
| Indivior Inc. | 2 | $41 |
| Hologic Sales And Service, LLC | 2 | $41 |
| Amarin Pharma, Inc. | 3 | $40 |
| Antares Pharma, Inc. | 2 | $35 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Nalpropion Pharmaceuticals LLC | 2 | $26 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Titan Pharmaceuticals, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$2,313 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 64 | $123,397 |
| OzempicSemaglutide | 79 | $106,103 |
| JardianceEmpagliflozin | 61 | $87,500 |
| JanuviaSitagliptin Phosphate | 46 | $69,345 |
| MounjaroTirzepatide | 34 | $49,456 |
| EliquisApixaban | 36 | $39,118 |
| FarxigaDapagliflozin Propanediol | 21 | $24,872 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,719 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 110 | $15,498 |
| LinzessLinaclotide | 11 | $14,731 |
| MyrbetriqMirabegron | 20 | $13,680 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $11,619 |
| Repatha SureclickEvolocumab | 12 | $10,870 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $10,206 |
| VascepaIcosapent Ethyl | 17 | $10,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $285 | $172,85398 claims |
| Novo NordiskOzempic | $312 | $106,10379 claims |
| Boehringer IngelheimJardiance | $42 | $87,50061 claims |
| MerckJanuvia, Lagevrio (Eua) | $17 | $76,73558 claims |
| PfizerEliquis | $201 | $39,11836 claims |
| AstraZenecaFarxiga, Symbicort | $425 | $30,05037 claims |
| GSKTrelegy Ellipta | $88 | $16,71916 claims |
| AbbVieLinzess, Synthroid | $114 | $16,53643 claims |
| Indivior Inc.Suboxone | $41 | $10,20625 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $60 | $8,78412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Mansfield
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.